Abstracts tagged "Uric Acid, Urate"

Abstract Number: 1111 • ACR Convergence 2023
Urate-Lowering Therapy Is Associated with a Reduced Risk of Arrhythmias: A Systematic Review and Meta-analysis
Palapun Waitayangkoon¹, Tatchaya Kanthajan² and Thiratest Leesutipornchai³, ¹MetroWest Medical Center, Framingham, MA, ²Srinakharinwirot University, Bangkok, Thailand, ³University of Hawaii, Honolulu, HI
Background/Purpose: Recent studies have suggested that hyperuricemia is significantly associated with an increased prevalence of atrial and ventricular arrhythmias and urate-lowering therapy (ULT) may provide…
Abstract Number: 0234 • ACR Convergence 2023
Identifying Optimal Serum Urate Levels to Reduce Gout Flares in Patients Taking Urate Lowering Therapy: A Post-hoc Cohort Analysis of CARES with Consideration of Drop-out
Sara Tedeschi¹, Keigo Hayashi¹, Yuqing Zhang², Hyon K. Choi³ and Daniel Solomon¹, ¹Brigham and Women's Hospital, Boston, MA, ²Division of Rheumatology, Allergy, and Immunology, Department of Medicine, Massachusetts General Hospital, Boston, MA, ³Massachusetts General Hospital and Harvard Medical School, Lexington, MA
Background/Purpose: ACR gout treatment guidelines recommend a target serum urate (SU) of < 6 mg/dL and anti-inflammatory flare prophylaxis for at least 3-6 months after…
Abstract Number: 1112 • ACR Convergence 2023
AR882, a Potent Uricosuric Agent, Shows Favorable Uric Acid Excretion Profile Following Multiple Doses
Zancong Shen¹, Elizabeth Polvent², sarah Morris³, Rongzi Yan⁴, Shunqi Yan⁵, Robert Keenan⁶ and Li-Tain Yeh⁷, ¹Arthrosi Therapeutics, San Diego, CA, ²Arthrosi Therapeutics, Inc., Roseville, CA, ³Arthrosi Therapeutics Inc, San Diego, CA, ⁴Arthrosi Therapeutics, Inc, Irvine, CA, ⁵Arthrosi Therapeutics, Inc., Laguna Hills, CA, ⁶Arthrosi Therapeutics, Chapel Hill, NC, ⁷Arthrosi Therapeutics, Inc., Irvine, CA
Background/Purpose: The uric acid transporter inhibitor (URAT1) is responsible for the reabsorption of filtered uric acid from the renal tubular lumen. Uricosuric agents inhibit URAT1…
Abstract Number: 0237 • ACR Convergence 2023
Oral Urate-Lowering Therapy Use and Efficacy Following Pegloticase Treatment: Findings from a Rheumatology Network Database
Lissa Padnick-Silver¹, Andrew Concoff², Hong-Ye Gao¹, Qianhong Fu¹, Brian LaMoreaux¹ and N. Lawrence Edwards³, ¹Horizon Therapeutics, Deerfield, IL, ²United Rheumatology, Happauge, NY, ³University of Florida College of Medicine, Gainesville, FL
Background/Purpose: Pegloticase, a recombinant pegylated uricase, rapidly reduces serum urate (SU) in patients refractory to/intolerant of oral urate-lowering therapies (ULTs).1,2 However, pegloticase is generally used…
Abstract Number: 1145 • ACR Convergence 2023
Human Cardiovascular Disease Model Provides Transcriptomic Evidence of Cardiovascular Risk Associated with Febuxostat
Ryan Feaver¹, Scott Bowers², Banumathi Cole¹, Steve Hoang¹, Mark Lawson¹, Justin Taylor¹, Brian LaMoreaux², Lin Zhao², Brad R Henke¹, Brian Johns¹, Andrew C Nyborg², Brian R Wamhoff¹ and Rob Figler¹, ¹HemoShear Therapeutics, Charlottesville, VA, ²Horizon Therapeutics, Deerfield, IL
Background/Purpose: Gout is a chronic inflammatory arthritis that is undertreated and managed with the xanthine oxidase inhibitors febuxostat or allopurinol. Despite the United States Food…
Abstract Number: 0240 • ACR Convergence 2023
Gout: A Gateway to Chronic Opioid Use?
Lindsay Helget¹, Bryant England¹, Punyasha Roul¹, Harlan Sayles¹, Tuhina Neogi², James O'Dell¹ and Ted R Mikuls³, ¹University of Nebraska Medical Center, Omaha, NE, ²Boston University School of Medicine, Boston, MA, ³Division of Rheumatology and Immunology, University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Painful gout flares often lead to healthcare visits which, based on prior reports, results in the use of opioid therapy for flare management, despite…
Abstract Number: 1204 • ACR Convergence 2023
Understanding Community Perspectives on Disease Management: A Social Media Analysis of Gout Care Strategies
Maurice Flurie¹, Monica Converse¹, Christopher Parker², Brian LaMoreaux³, Daniel Hernandez⁴, N. Lawrence Edwards⁵, Gary Ho¹, Kristina Davidson⁶, E. Robert Wassman¹, Christopher DeFelice¹ and Maria Picone¹, ¹TREND Community, Philadelphia, PA, ²TREND Community, Austin, TX, ³Horizon Therapeutics, Deerfield, IL, ⁴Global Healthy Living Foundation, St. Johns, FL, ⁵University of Florida College of Medicine, Gainesville, FL, ⁶Horizon Therapeutics, Dublin, Ireland
Background/Purpose: To comprehensively understand the impact of disease management strategies, it is essential to understand the patient perspective. Gout is a chronic inflammatory arthritis characterized…
Abstract Number: 0241 • ACR Convergence 2023
Gout Flares During the Initiation and Escalation of Treat-to-Target Urate Lowering Therapy: A Post-hoc Analysis of a Randomized Multicenter Comparative Effectiveness Trial
Austin Barry¹, Lindsay Helget¹, Maria Androsenko², Hongsheng Wu³, Bridget Kramer¹, Jeff Newcomb⁴, Mary Brophy³, Anne Davis-Karim⁵, Bryant England¹, Ryan Ferguson³, Michael Pillinger⁶, Tuhina Neogi⁷, Paul Palevsky⁸, James O'Dell¹ and Ted R Mikuls⁹, ¹University of Nebraska Medical Center, Omaha, NE, ²Department of VA, Newton, MA, ³Boston VA, Boston, MA, ⁴Omaha VA, Omaha, NE, ⁵Albuquerque VA, Albuquerque, NM, ⁶New York University Grossman School of Medicine, New York, NY, ⁷Boston University School of Medicine, Boston, MA, ⁸University of Pittsburgh, Pittsburgh, PA, ⁹Division of Rheumatology and Immunology, University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Initiating urate-lowering therapy (ULT) in gout is known to precipitate flares, which can lead to decreased adherence and suboptimal outcomes. Until recently, there has…
Abstract Number: 1805 • ACR Convergence 2023
Longitudinal Changes in Serum Urate Associate Minimally with Changes in Daily Alcohol Intake
Sho Fukui¹, Masato Okada², Tomohiro Shinozaki³, Takahiro Asano², Takehiro Nakai², Hiromichi Tamaki², Mitsumasa Kishimoto⁴, Hiroshi Hasegawa⁵, Takeaki Matsuda⁵, Javier Marrugo¹, Sara Tedeschi¹ and Daniel Solomon⁶, ¹Brigham and Women's Hospital, Boston, MA, ²St. Luke's International Hospital, Tokyo, Japan, ³Tokyo University of Science, Tokyo, Japan, ⁴Kyorin University School of Medicine, Yokohoma, Japan, ⁵Kyorin University, Tokyo, Japan, ⁶Brigham and Women's Hospital, Newton, MA
Background/Purpose: Cross-sectional epidemiologic studies support a direct relationship between alcohol intake and serum urate (SU). These observations are parts of the basis for gout recommendations…
Abstract Number: 0244 • ACR Convergence 2023
Efficacy and Safety of AR882, a Selective Uric Acid Transporter 1 (URAT1) Inhibitor, in Gout Patients with Various Baseline Characteristics Following 12-Week Treatment in Patients
James Cheng-Chung Wei¹, Roy Fleischmann², sarah Morris³, Vijay Hingorani⁴, Elizabeth Polvent⁵, Zancong Shen⁶, Shunqi Yan⁷, Li-Tain Yeh⁸ and Robert Keenan⁹, ¹Chung Shan Medical University Hospital, Department of Rheumatology, Taichung, Taiwan, ²Division of Rheumatology, University of Texas Southwestern Medical Center, Metroplex Clinical Research Center, Dallas, TX, ³Arthrosi Therapeutics Inc, San Diego, CA, ⁴Vanguard Healthsciences, Inc., San Diego, CA, ⁵Arthrosi Therapeutics, Inc., Roseville, CA, ⁶Arthrosi Therapeutics, San Diego, CA, ⁷Arthrosi Therapeutics, Inc., Laguna Hills, CA, ⁸Arthrosi Therapeutics, Inc., Irvine, CA, ⁹Arthrosi Therapeutics, Chapel Hill, NC
Background/Purpose: AR882 is a novel, potent, and selective URAT1inhibitor in development for the treatment of gout and tophaceous gout. AR882-202 was a global, multi-center, randomized,…
Abstract Number: 1810 • ACR Convergence 2023
Alcohol Consumption Amount, Type of Beverage, and Gender, All Matters to Serum Uric Acid Levels
Jiwon Hwang¹, Sungjun Hong², Kyunga Kim³, Jinhee Hur⁴, Yoosoo Chang⁵, Joong Kyong Ahn⁶ and Mira Kang⁷, ¹Division of Rheumatology, Department of Internal Medicine, Samsung Changwon Hospital, Sungkyunkwan University School of Medicine, Changwon-si, South Korea, ²Department of Digital Health, Samsung Advanced Institute of Health Sciences and Technology (SAIHST), Sungkyunkwan University, Seoul, South Korea, ³Department of Digital Health, Samsung Advanced Institute of Health Sciences and Technology (SAIHST), Sungkyunkwan University; Biomedical Statistics Center, Data Science Research Institute, Research Institute for Future Medicine, Samsung Medical Center; Department of Data Convergence & Future Medicine, Sungkyunkwan University School of Medicine, Seoul, South Korea, ⁴Department of Food Science and Biotechnology, Sungkyunkwan University; Food Clinical Research Center, Institute of Biotechnology and Bioengineering, Sungkyunkwan University, Suwon, South Korea, ⁵Center for Cohort Studies, Total Healthcare Center, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine; Department of Occupational and Environmental Medicine, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, South Korea, ⁶Division of Rheumatology, Department of Internal Medicine, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, South Korea, ⁷Department of Digital Health, Samsung Advanced Institute of Health Sciences and Technology (SAIHST), Sungkyunkwan University; Health Promotion Center, Samsung Medical Center, Sungkyunkwan University School of Medicine; Digital Transformation Center, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea
Background/Purpose: Alcohol intake has been known to be interrelated with hyperuricemia and gout. However, the results of its influence are conflicting on serum uric acid…
Abstract Number: 0245 • ACR Convergence 2023
Impact of Combined Intervention with Clinical Nurse Specialist in the Management of Cardiovascular Risk in Patients with Gout
Claudia Maria Gomez¹, Patricio Cardoso Peñafiel¹, Jose Antonio Angel-Sesmero¹, Marta Novella-Navarro² and Enrique Calvo-Aranda¹, ¹Hospital Universitario Infanta Leonor, Madrid, Spain, ²Hospital Universitario La Paz, Madrid, Spain
Background/Purpose: Gout is associated with increased cardiovascular risk (CVR). Traditional CVR factors (CVRF) are frequently present in patients with gout, further worsening the prognosis. Several…
Abstract Number: 1811 • ACR Convergence 2023
Strong Relationships Between Body Component Changes and Serum Uric Acid Variability
Jiwon Hwang¹, Mi Yeon Lee², Yeonghee Eun³ and Joong Kyong Ahn³, ¹Division of Rheumatology, Department of Internal Medicine, Samsung Changwon Hospital, Sungkyunkwan University School of Medicine, Changwon-si, South Korea, ²Division of Biostatistics, Department of R&D Management, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, South Korea, ³Division of Rheumatology, Department of Internal Medicine, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, South Korea
Background/Purpose: Obesity has a well-known relationship with higher serum uric acid (SUA) levels. Skeletal muscles are another site for producing uric acid as the endogenous…
Abstract Number: 0251 • ACR Convergence 2023
Sodium-glucose Cotransporter-2 Inhibitor Initiation, Risk of Recurrent Gout Flares, and Mortality in Patients with Gout and Type 2 Diabetes: A Population-based Cohort Study
Jie Wei¹, Hyon K. Choi², Nicola Dalbeth³, Xiaoxiao Li⁴, Changjun Li⁵, Chao Zeng⁶, Guanghua Lei⁶ and Yuqing Zhang⁷, ¹Health Management Center, Xiangya Hospital Central South University, Changsha, China, ²Massachusetts General Hospital and Harvard Medical School, Lexington, MA, ³University of Auckland, Auckland, New Zealand, ⁴Key Laboratory of Aging-related Bone and Joint Diseases Prevention and Treatment, Ministry of Education, Xiangya Hospital, Central South University, Changsha, China, ⁵National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, China, ⁶Department of Orthopaedics, Xiangya Hospital, Central South University, Changsha, China, ⁷Division of Rheumatology, Allergy, and Immunology, Department of Medicine, Massachusetts General Hospital, Boston, MA
Background/Purpose: Recurrent flares are the hallmark of clinical manifestation of gout. Sodium-glucose cotransporter-2 inhibitors (SGLT2i) were associated with a lower risk of incident gout; however,…
Abstract Number: 1816 • ACR Convergence 2023
Hyperuricemia – Especially “Metabolic Hyperuricemia” – Is Independently Associated with Higher Risk of Fatty Liver
Janis Timsans¹, Jenni Kauppi¹, Hannu Kautiainen² and Markku Kauppi³, ¹Päijät-Häme Central Hospital, Lahti, Finland, ²University of Helsinki, Folkhälsan Research Center, Helsinki, Finland, ³University of Helsinki, Helsinki, Finland
Background/Purpose: Elevated serum uric acid (SUA) level is rather prevalent in the general population, and it is associated with numerous comorbidities and mortality. Etiology of…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].